Akums Drugs & Pharmaceuticals' Q1 FY 2025-26 Quarterly Results

Result Summary

• Akums Drugs & Pharmaceuticals Ltd reported a 10.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 2.4%.
• Its expenses for the quarter were down by 3.3% QoQ and up 1.8% YoY.
• The net profit decreased 263.9% QoQ and increased 5.7% YoY.
• The earnings per share (EPS) of Akums Drugs & Pharmaceuticals Ltd stood at 4.2 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Akums Drugs & Pharmaceuticals Ltd is a prominent company operating within the pharmaceutical industry. The company primarily focuses on manufacturing and distributing a wide range of pharmaceutical formulations. These include tablets, capsules, liquid orals, injectables, ointments, and other therapeutic products. Akums Drugs & Pharmaceuticals Ltd is recognized for its substantial manufacturing capabilities, catering to a diverse clientele. The company is known for its commitment to quality and innovation, aligning with industry standards to meet the regulatory requirements. Any recent major developments or other specific company details beyond the scope of the provided data remain unspecified.

Revenue

In the first quarter of fiscal year 2026 (Q1FY26), Akums Drugs & Pharmaceuticals Ltd reported a total income of ₹1050.76 crores. This represents a 10.1% increase compared to the previous quarter (Q4FY25), where total income was ₹954.45 crores. Year-over-year (YoY), there was a 2.4% increase from Q1FY25, which had a total income of ₹1025.66 crores. These figures indicate a positive change in revenue both on a quarterly and annual basis, suggesting improvements in sales or other income-generating activities during this period.

Profitability

The profit before tax (PBT) for Q1FY26 was ₹95.65 crores, a significant turnaround from the previous quarter (Q4FY25), which saw a loss of ₹32.88 crores. This marks a quarter-over-quarter (QoQ) change of -390.9%. Compared to the same quarter last year (Q1FY25), where the PBT was ₹87.48 crores, there's a YoY increase of 9.3%. The tax expense for Q1FY26 stood at ₹30.96 crores, reflecting a substantial increase both QoQ (370.5%) and YoY (17.9%). The profit after tax (PAT) for Q1FY26 was ₹64.69 crores, compared to a loss of ₹39.47 crores in Q4FY25, marking a QoQ change of -263.9%. The YoY change from Q1FY25's PAT of ₹61.21 crores is 5.7%. Earnings per share (EPS) remained at ₹4.20, identical to Q1FY25, marking no change YoY, while showing a significant recovery from a negative EPS of ₹-2.90 in Q4FY25.

Operating Metrics

Total expenses for Q1FY26 were reported at ₹955.12 crores, which is a decrease of 3.3% from the previous quarter (Q4FY25), where expenses were ₹987.55 crores. Year-over-year, total expenses increased by 1.8% from ₹938.18 crores in Q1FY25. The reduction in expenses on a quarterly basis, coupled with an increase in income, reflects changes in the company's operational efficiency or cost management strategies. These metrics are essential in understanding the company's operational health and efficiency in managing its resources relative to the revenue generated during the quarter.